Slow-SPEED-NL: study protocol for a remote trial of exercise for Parkinson’s disease prevention
Objective: To determine the feasibility and preliminary efficacy of a remote exercise intervention in prodromal Parkinson’s disease (PD). Background: Disease-slowing interventions have been ineffective in…Mortality Rate, Cause of Death and Factors Associated with Mortality in Late Stage Parkinson’s Disease
Objective: The aim was to carry out a long-term follow-up of a cohort of patients in late stage Parkinson’s disease (PD) with focus on mortality…The effects of DL-3-n-butylphthalide in patients with mild cognitive impairment due to Parkinson’s disease: A multicenter, randomized, double-blind, placebo-controlled trial
Objective: To assess the therapeutic effect of DL-3-n-butylphthalide on cognitive impairment associated with Parkinson’s disease (PD). Background: PD associated cognitive impairment are attracting attention because…Neuroprotective Action of Betulin in Parkinson’s disease: Alleviating Mitochondrial Dysfunction and Oxidative Stress-Induced Apoptosis in rat model
Objective: The objective of this study was to evaluate the neuroprotective efficacy of Betulin in MPTP-induced mice models of Parkinson's disease (PD), focusing on its…Characterisation of the pharmacokinetic profile of amantadine in the common marmoset
Objective: To determine the pharmacokinetic (PK) profile of amantadine in the common marmoset (Callithrix jacchus). Background: Amantadine is currently approved for the treatment of L-3,4-dihydroxyphenylalanine…Loganic Acid Alleviates the Bidirectional Olfactory-Brain NLRP3 Inflammasome Activation and Rescues Dopaminergic Neurons in Experimental Models of Parkinson’s Disease
Objective: The study aimed to delineate the molecular mechanism involved in bidirectional olfactory-brain dysfunction through the NLRP3 inflammasome signaling activation in in-vitro and in-vivo model…Effect of various mGlu2 and mGlu2/3 activators on parkinsonism: a sub-analysis in the MPTP-lesioned primate
Objective: To evaluate the effect of the metabotropic glutamate 2/3 (mGlu2/3) orthosteric activators (OAs) LY-354,740 and LY-404,039, as well as the effects of the metabotropic…First-In-Human Single and Multiple Ascending Dose Trial Design of LY3962681, a Novel Intrathecally Delivered siRNA Targeting α-synuclein mRNA for the Treatment of Patients with Parkinson’s Disease
Objective: Development of a Phase 1 clinical trial evaluating LY3962681, a novel, intrathecally delivered siRNA directly targeting α-synucleinmRNA (SNCA) to reduce α-synuclein protein (ASYN), for the treatment of…Changes in Gut Microbiome of Parkinson’s disease Patients using Photobiomodulation Therapy
Objective: To assess changes in the gut microbiome composition in a small cohort of clinical trial participants using photobiomodulation (light therapy) over a five-year period…ENLITE PD – A Dose Selection Trial of Light Therapy for Impaired Sleep in Parkinson’s Disease
Objective: To determine if either once or twice-daily bright white light therapy (BWLT) improves sleep sufficiently relative to two control LT conditions to warrant proceeding…
- « Previous Page
- 1
- …
- 408
- 409
- 410
- 411
- 412
- …
- 1942
- Next Page »